Russia Unveils Colon Cancer Vaccine After Promising Trial Results

Context

• Russia’s Federal Medical Biological Agency (FMBA) announced completion of preclinical trials for a colon cancer vaccine.
• Revealed by Veronika Skvortsova, FMBA Head, at the 10th Eastern Economic Forum (EEF), Vladivostok (Sep 2025).
• Marks a significant step in cancer immunotherapy, especially for colorectal cancer, one of the leading causes of cancer deaths globally.
• Research Findings

Preclinical trials showed:

• Tumour reduction: 60–80%
• Slowed progression of disease
• Improved survival rates in test subjects
• No adverse effects, even with multiple doses
• Mechanism – How It Works
• Unlike preventive vaccines (e.g., HPV), this is a therapeutic cancer vaccine.

Designed to:

• Activate the immune system
• Enhance recognition of tumour antigens
• Slow progression & extend survival

Next Steps

• Vaccine labeled “ready for use,” but pending regulatory approval.
• Once approved, may become the world’s first colon cancer vaccine developed in Russia, available for clinical use domestically and globally.

Other Vaccines in FMBA Pipeline

• Glioblastoma (brain cancer) – limited treatment options
• Melanoma (including ocular types) – advanced-stage trials, promising results

Key Takeaways for Exams

• Target: Colorectal (colon) cancer
• Announced by: Veronika Skvortsova, FMBA
• Event: 10th Eastern Economic Forum, Vladivostok (Sep 3–6, 2025)
• Effectiveness: Tumour shrinkage (60–80%), better survival
• Status: Awaiting regulatory approval